Mersana Therapeutics (MRSN) Competitors $0.35 +0.02 (+5.63%) Closing price 04:00 PM EasternExtended Trading$0.35 -0.01 (-2.17%) As of 05:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock MRSN vs. NBTX, DMAC, CGC, FULC, IPHA, DERM, ACRS, MOLN, PBYI, and KRROShould you be buying Mersana Therapeutics stock or one of its competitors? The main competitors of Mersana Therapeutics include Nanobiotix (NBTX), DiaMedica Therapeutics (DMAC), Canopy Growth (CGC), Fulcrum Therapeutics (FULC), Innate Pharma (IPHA), Journey Medical (DERM), Aclaris Therapeutics (ACRS), Molecular Partners (MOLN), Puma Biotechnology (PBYI), and Korro Bio (KRRO). These companies are all part of the "pharmaceutical products" industry. Mersana Therapeutics vs. Nanobiotix DiaMedica Therapeutics Canopy Growth Fulcrum Therapeutics Innate Pharma Journey Medical Aclaris Therapeutics Molecular Partners Puma Biotechnology Korro Bio Mersana Therapeutics (NASDAQ:MRSN) and Nanobiotix (NASDAQ:NBTX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, profitability, dividends, analyst recommendations, earnings, community ranking, institutional ownership, media sentiment and risk. Which has preferable valuation and earnings, MRSN or NBTX? Nanobiotix has lower revenue, but higher earnings than Mersana Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMersana Therapeutics$40.50M1.09-$171.67M-$0.56-0.63Nanobiotix-$11.61M-13.56-$42.97MN/AN/A Do analysts rate MRSN or NBTX? Mersana Therapeutics presently has a consensus target price of $4.00, suggesting a potential upside of 1,027.71%. Nanobiotix has a consensus target price of $8.00, suggesting a potential upside of 139.52%. Given Mersana Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Mersana Therapeutics is more favorable than Nanobiotix.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mersana Therapeutics 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.00Nanobiotix 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67 Does the media refer more to MRSN or NBTX? In the previous week, Nanobiotix had 2 more articles in the media than Mersana Therapeutics. MarketBeat recorded 2 mentions for Nanobiotix and 0 mentions for Mersana Therapeutics. Mersana Therapeutics' average media sentiment score of 1.89 beat Nanobiotix's score of 0.62 indicating that Mersana Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Mersana Therapeutics Very Positive Nanobiotix Positive Which has more volatility & risk, MRSN or NBTX? Mersana Therapeutics has a beta of 1.68, meaning that its share price is 68% more volatile than the S&P 500. Comparatively, Nanobiotix has a beta of 0.26, meaning that its share price is 74% less volatile than the S&P 500. Does the MarketBeat Community prefer MRSN or NBTX? Mersana Therapeutics received 240 more outperform votes than Nanobiotix when rated by MarketBeat users. Likewise, 66.14% of users gave Mersana Therapeutics an outperform vote while only 63.16% of users gave Nanobiotix an outperform vote. CompanyUnderperformOutperformMersana TherapeuticsOutperform Votes25266.14% Underperform Votes12933.86% NanobiotixOutperform Votes1263.16% Underperform Votes736.84% Do insiders and institutionals have more ownership in MRSN or NBTX? 93.9% of Mersana Therapeutics shares are owned by institutional investors. Comparatively, 38.8% of Nanobiotix shares are owned by institutional investors. 11.8% of Mersana Therapeutics shares are owned by company insiders. Comparatively, 3.5% of Nanobiotix shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Is MRSN or NBTX more profitable? Nanobiotix has a net margin of 0.00% compared to Mersana Therapeutics' net margin of -214.20%. Nanobiotix's return on equity of 0.00% beat Mersana Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Mersana Therapeutics-214.20% -401.37% -38.61% Nanobiotix N/A N/A N/A SummaryMersana Therapeutics beats Nanobiotix on 12 of the 17 factors compared between the two stocks. Get Mersana Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MRSN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MRSN vs. The Competition Export to ExcelMetricMersana TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$44.21M$6.45B$5.29B$7.35BDividend YieldN/A3.24%5.12%4.31%P/E Ratio-0.586.8821.7117.77Price / Sales1.09231.35379.3997.68Price / CashN/A65.6738.2234.64Price / Book1.145.916.443.98Net Income-$171.67M$142.72M$3.21B$247.44M7 Day Performance35.69%7.98%5.24%4.44%1 Month Performance-25.95%-13.91%-9.49%-7.73%1 Year Performance-89.92%-9.98%11.01%1.28% Mersana Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MRSNMersana Therapeutics3.3552 of 5 stars$0.35+5.6%$4.00+1,027.7%-91.1%$44.21M$40.50M-0.58150Positive NewsNBTXNanobiotix1.776 of 5 stars$3.17-3.1%$8.00+152.4%-40.6%$149.41M$36.22M0.00100Gap UpDMACDiaMedica Therapeutics1.2027 of 5 stars$3.48-0.6%$8.00+129.9%+46.4%$149.14MN/A-6.2120Short Interest ↑Gap DownCGCCanopy Growth2.2289 of 5 stars$0.93+1.1%$2.00+114.9%-82.4%$147.59M$276.75M-0.243,150Options VolumeNews CoverageFULCFulcrum Therapeutics1.9691 of 5 stars$2.72+8.4%$8.63+217.1%-58.7%$146.82M$80M-8.77100Short Interest ↓Positive NewsIPHAInnate Pharma1.9488 of 5 stars$1.74-5.2%$11.50+562.8%-25.1%$145.45M$12.63M0.00220News CoverageGap DownDERMJourney Medical2.4046 of 5 stars$6.96-3.2%$9.88+41.9%+63.4%$145.39M$56.13M-7.4090Short Interest ↑High Trading VolumeACRSAclaris Therapeutics2.5454 of 5 stars$1.33-5.0%$11.67+777.2%-7.4%$143.53M$18.72M-2.56100Positive NewsMOLNMolecular Partners2.1007 of 5 stars$3.55-0.6%$12.00+238.0%-8.7%$143.33M$4.97M-1.65180News CoverageGap UpPBYIPuma Biotechnology3.3388 of 5 stars$2.83-2.4%$7.00+147.3%-43.5%$140.40M$230.47M5.90200Analyst UpgradeNews CoverageKRROKorro Bio1.5331 of 5 stars$14.93+3.8%$136.33+813.2%-81.7%$140.18M$2.27M-1.5970Analyst ForecastNews CoverageGap Down Related Companies and Tools Related Companies NBTX Competitors DMAC Competitors CGC Competitors FULC Competitors IPHA Competitors DERM Competitors ACRS Competitors MOLN Competitors PBYI Competitors KRRO Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MRSN) was last updated on 4/17/2025 by MarketBeat.com Staff From Our PartnersGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredAmazon ShockerJeff Bezos quietly backing world-changing tech (not AI) The Amazon founder is quietly advancing a radical t...Stansberry Research | SponsoredDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | Sponsored🥾⛏️👷♂️ What I Learned From Numerous Mine Visits...Twenty years ago, I made a decision that changed my life. Instead of sitting behind a desk analyzing mining...Golden Portfolio | SponsoredCaught on Camera: Elon Musk’s “Area 51”You won’t believe what tech legend Jeff Brown found in what he calls Elon Musk’s “Area 51.” (Click here to see...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mersana Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Mersana Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy MRSN Stock Free MRSN Stock Alerts